中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 4
Apr.  2010
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2010  >  26(4): 432-433

The therapeutic effect of ursodeoxycholic acid capsules in patients with primary biliary cirrhosis

  • Published Date: 2010-04-20
    Abstract
  • Objective To determine the therapeutic effect of ursodeoxycholic acid capsules in patients with primary biliary cirrhosis.Methods Sixty patients of primary biliary cirrhosis were randomly divided into treatment group and control group.Liver protection and supportive treatment were given for the two groups.Ursodeoxycholic acid capsules (10mg/kg daily) was given for the treatment group (Usage and dosage: for 60kg Weight, two times a day, 1 grain in the morning and evening;for 80kg weight, three times a day, 1 grain in the morning, noon and evening;for 100kg weight, three times a day, 1 grain in the morning and noon, and 2 grains in the evening) .Ursodeoxycholic acid tablets (made in china) 8-10mg/Kg daily was given for the control group.The treatment duration was 26 weeks in both groups.Results Alanine aminotransferase (ALT) , γ-glutamyl transferase (GGT) and serum total bilirubin (TBIL) were significantly improved in the treatment group than the control group (P<0.01) .The skin itching and fatigue situations were also improved in treatment group than the control group (P<0.05) .Conclusion Compared with ursodeoxycholic acid tablets, ursodeoxycholic acid capsules can quickly and effectively reduce the skin itching and fatigue in primary biliary cirrhosis, and improve liver function indexes.

     

    • FullText(HTML)
    • References(3)
  • [1]Beuers U.Drug Insight:mechanisims and sites of action of ursode-oxycholic acid in cholestasis[J].Nature Clinical Practice Gastroen-terology and Hepatology, 2006, 3 (6) ∶318-328.
    [2]Mitsuyoshi H, Nakashima T, Sumida Y, et al.Ursodeoxycholic acidprotects hepatocytes against osidative injury via induction of antioxida-nts[J].Biochem Biophys Res Commun, 1999, 263 (2) ∶537-542.
    [3]Von Ritter C, Sreejayan N, Müller I, et al.Ursodeoxycholic acid re-duces lipid peroxidation and mucin secretagougue activity of humanbile in cholesterol Gallstone disease[J].Gastroenterology, 1998, 114 (4) ∶A548-A549.
    • Relative Articles

  • Relative Articles

    [1]Junfang SHUAI, Ziyan HAN. Research advances in obeticholic acid and fibrates in treatment of primary biliary cholangitis with poor response or intolerance to ursodeoxycholic acid[J]. Journal of Clinical Hepatology, 2022, 38(4): 913-917. doi: 10.3969/j.issn.1001-5256.2022.04.035
    [2]Lili ZHANG, Aiwen GENG, Chuanwang QI, Jianchun XIAN. Association between immunoglobulin G4-related diseases and autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2021, 37(12): 2972-2975. doi: 10.3969/j.issn.1001-5256.2021.12.050
    [3]Wang Lu, Sun KeShuai, Han ZheYi, Guo ZhangCun, Jia Gui, Gao KeNa, Zhang YaWei, Han Ying. Clinical effect of fenofibrate combined with ursodeoxycholic acid in treatment of primary biliary cholangitis patients with poor response to ursodeoxycholic acid alone[J]. Journal of Clinical Hepatology, 2018, 34(11): 2368-2372. doi: 10.3969/j.issn.1001-5256.2018.11.020
    [4]Shi YiWen, You Hong. Therapeutic strategies for patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid[J]. Journal of Clinical Hepatology, 2017, 33(11): 2101-2104. doi: 10.3969/j.issn.1001-5256.2017.11.010
    [5]Wu LiHong, Han Ying. Application and role of fibrates in treatment of primary biliary cholangitis and related mechanisms[J]. Journal of Clinical Hepatology, 2016, 32(12): 2403-2406. doi: 10.3969/j.issn.1001-5256.2016.12.038
    [6]Li Lei, Li Bing, Ding HuiGuo. Effect of ursodeoxycholic acid on bile secretion after endoscopic nasobiliary drainage in patients with cholestatic liver disease of various causes[J]. Journal of Clinical Hepatology, 2016, 32(3): 522-525. doi: 10.3969/j.issn.1001-5256.2016.03.026
    [7]Li YanMei, Wang QiXia, Ma Xiong. Research advances in treatment of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2016, 32(8): 1491-1496. doi: 10.3969/j.issn.1001-5256.2016.08.012
    [8]Li XiaoShu, Ceng Hui, Wang XianBo. Research progress in immunological mechanisms for primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(8): 1365-1369. doi: 10.3969/j.issn.1001-5256.2015.08.048
    [9]Shi GuangYing, Ma XiaoYuan, Xie JingDong. Changes in T lymphocyte subsets and cytokines in peripheral blood of patients with primary biliary cirrhosis after treatment with different doses of ursodeoxycholic acid[J]. Journal of Clinical Hepatology, 2015, 31(9): 1447-1451. doi: 10.3969/j.issn.1001-5256.2015.09.020
    [10]Li Bing, Shao Qing, Niu XiaoXia, Zhang Jian, Chen GuoFeng. Clinical features and diagnosis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome[J]. Journal of Clinical Hepatology, 2014, 30(5): 413-416. doi: 10.3969/j.issn.1001-5256.2014.05.007
    [11]Wang Qian, Yao DingKang. Research progress in medical treatment of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(5): 462-465. doi: 10.3969/j.issn.1001-5256.2014.05.022
    [12]Wang WeiBin, Zhu YouFu. A brief discussion on pathogenesis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(11): 805-809. doi: 10.3969/j.issn.1001-5256.2013.11.002
    [13]Qin Hua, Bai ShiShan. Advances in treatment of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(9): 719-721. doi: 10.3969/j.issn.1001-5256.2013.09.023
    [14]Lu WeiTing, Jiang XingHuo, Guo HaiYan, Zhao JianXue. Clinical features of primary biliary cirrhosis: a clinical analysis of 70 cases[J]. Journal of Clinical Hepatology, 2013, 29(12): 926-928. doi: 10.3969/j.issn.1001-5256.2013.12.013
    [15]Zhou SuMin, Gao PuJun. Advancement in the treatment of two subtypes of autoimmune pancreatitis[J]. Journal of Clinical Hepatology, 2011, 27(11): 1219-1221.
    [16]Zhou SuMin, Gao PuJun, Gao RunPing. A case report of autoimmune pancreatitis[J]. Journal of Clinical Hepatology, 2011, 27(4): 424+43.
    [17]Wang LiXia, Lu ShuMing, Duan ZhiJun. One case of primary billiary cirrhosis and sjgren syndrome[J]. Journal of Clinical Hepatology, 2011, 27(6): 650+65.
    [18]Zhang FengChun. Primary biliary cirrhosis and liver disease secondary to diffuse connective tissue diseases[J]. Journal of Clinical Hepatology, 2011, 27(6): 588-590.
    [19]Hu YuLin, Zhang Rong. Clinical features, diagnosis and treatment of autoimmune pancreatitis[J]. Journal of Clinical Hepatology, 2010, 26(5): 487-489.
    [20]Wang ZhiBin, Zhang Chang, Li JunXiang.

    A case report of acroscleroderma overlap syndrome in primary biliary cirrhosis

    [J]. Journal of Clinical Hepatology, 2010, 26(4): 434-435.
    • Supplements(0)
    • Cited By
  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-042024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-030255075100
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 1.2 %FULLTEXT: 1.2 %META: 96.4 %META: 96.4 %PDF: 2.4 %PDF: 2.4 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 10.0 %其他: 10.0 %其他: 2.8 %其他: 2.8 %Auckland: 0.1 %Auckland: 0.1 %Baden: 0.1 %Baden: 0.1 %Bass Hill: 0.1 %Bass Hill: 0.1 %Canton: 0.4 %Canton: 0.4 %Central District: 2.0 %Central District: 2.0 %China: 0.2 %China: 0.2 %Dacula: 0.1 %Dacula: 0.1 %Halfweg: 0.1 %Halfweg: 0.1 %Italy: 0.1 %Italy: 0.1 %Japan: 0.1 %Japan: 0.1 %Kao-sung: 0.1 %Kao-sung: 0.1 %Kennedy Town: 0.1 %Kennedy Town: 0.1 %Mongolia: 0.1 %Mongolia: 0.1 %North Point: 0.1 %North Point: 0.1 %Saitama: 0.4 %Saitama: 0.4 %Singapore: 0.1 %Singapore: 0.1 %Tuen Mun San Hui: 0.1 %Tuen Mun San Hui: 0.1 %United States: 0.1 %United States: 0.1 %[]: 0.8 %[]: 0.8 %上海: 7.8 %上海: 7.8 %上饶: 0.1 %上饶: 0.1 %东京: 0.3 %东京: 0.3 %东莞: 0.2 %东莞: 0.2 %东营: 0.1 %东营: 0.1 %中卫: 0.1 %中卫: 0.1 %中山: 0.1 %中山: 0.1 %临沂: 0.3 %临沂: 0.3 %云浮: 0.1 %云浮: 0.1 %伦敦: 0.1 %伦敦: 0.1 %佛山: 0.1 %佛山: 0.1 %佛罗里达州: 0.1 %佛罗里达州: 0.1 %佳木斯: 0.1 %佳木斯: 0.1 %保定: 0.1 %保定: 0.1 %元朗新墟: 0.1 %元朗新墟: 0.1 %凤凰城: 0.1 %凤凰城: 0.1 %加利福尼亚州: 0.3 %加利福尼亚州: 0.3 %加州: 0.1 %加州: 0.1 %北京: 9.7 %北京: 9.7 %匹兹堡: 0.1 %匹兹堡: 0.1 %南京: 0.5 %南京: 0.5 %南宁: 0.2 %南宁: 0.2 %南平: 0.1 %南平: 0.1 %南昌: 0.4 %南昌: 0.4 %南通: 0.1 %南通: 0.1 %厦门: 0.1 %厦门: 0.1 %台北: 0.3 %台北: 0.3 %台州: 0.1 %台州: 0.1 %合肥: 0.1 %合肥: 0.1 %吉林: 0.2 %吉林: 0.2 %呼和浩特: 0.2 %呼和浩特: 0.2 %哈尔滨: 0.1 %哈尔滨: 0.1 %唐山: 0.2 %唐山: 0.2 %商丘: 0.1 %商丘: 0.1 %喀拉拉: 0.1 %喀拉拉: 0.1 %嘉兴: 0.1 %嘉兴: 0.1 %圣保罗: 0.1 %圣保罗: 0.1 %埃德蒙顿: 0.1 %埃德蒙顿: 0.1 %墨尔本: 0.2 %墨尔本: 0.2 %墨西哥城: 0.1 %墨西哥城: 0.1 %多伦多: 0.1 %多伦多: 0.1 %大庆: 0.1 %大庆: 0.1 %大理: 0.1 %大理: 0.1 %大连: 0.1 %大连: 0.1 %天水围: 0.1 %天水围: 0.1 %天津: 0.9 %天津: 0.9 %太原: 0.1 %太原: 0.1 %奥克兰: 0.1 %奥克兰: 0.1 %安大略: 0.1 %安大略: 0.1 %安庆: 0.1 %安庆: 0.1 %安康: 0.1 %安康: 0.1 %官坑: 0.1 %官坑: 0.1 %宜春: 0.1 %宜春: 0.1 %宝鸡: 0.1 %宝鸡: 0.1 %宿迁: 0.1 %宿迁: 0.1 %密蘇里城: 0.1 %密蘇里城: 0.1 %巴彦淖尔: 0.1 %巴彦淖尔: 0.1 %布里斯班: 0.1 %布里斯班: 0.1 %常州: 0.1 %常州: 0.1 %广州: 1.8 %广州: 1.8 %廊坊: 0.1 %廊坊: 0.1 %延安: 0.1 %延安: 0.1 %张家口: 1.0 %张家口: 1.0 %徐州: 0.1 %徐州: 0.1 %怀化: 0.1 %怀化: 0.1 %悉尼: 0.2 %悉尼: 0.2 %惠州: 0.3 %惠州: 0.3 %意法半: 0.1 %意法半: 0.1 %成都: 0.6 %成都: 0.6 %扬州: 0.1 %扬州: 0.1 %承德: 0.1 %承德: 0.1 %抚顺: 0.1 %抚顺: 0.1 %拉斯维加斯: 0.1 %拉斯维加斯: 0.1 %揭阳: 0.1 %揭阳: 0.1 %新加坡: 0.4 %新加坡: 0.4 %无锡: 0.1 %无锡: 0.1 %旧金山: 0.1 %旧金山: 0.1 %昆明: 0.4 %昆明: 0.4 %晋城: 0.1 %晋城: 0.1 %朝阳: 0.1 %朝阳: 0.1 %来宾: 0.1 %来宾: 0.1 %杭州: 1.6 %杭州: 1.6 %枣庄: 0.1 %枣庄: 0.1 %柳州: 0.1 %柳州: 0.1 %栃木: 0.1 %栃木: 0.1 %株洲: 0.1 %株洲: 0.1 %森尼韦尔: 0.2 %森尼韦尔: 0.2 %武汉: 1.1 %武汉: 1.1 %氹仔: 0.1 %氹仔: 0.1 %沈阳: 0.4 %沈阳: 0.4 %沧州: 0.1 %沧州: 0.1 %泉州: 0.1 %泉州: 0.1 %泸州: 0.1 %泸州: 0.1 %泽西: 0.1 %泽西: 0.1 %洛杉矶: 0.2 %洛杉矶: 0.2 %洛阳: 0.4 %洛阳: 0.4 %济南: 0.4 %济南: 0.4 %济宁: 0.1 %济宁: 0.1 %海口: 0.1 %海口: 0.1 %淄博: 0.1 %淄博: 0.1 %深圳: 1.6 %深圳: 1.6 %温哥华: 0.1 %温哥华: 0.1 %温州: 0.1 %温州: 0.1 %湛江: 0.1 %湛江: 0.1 %滨州: 0.1 %滨州: 0.1 %漳州: 0.1 %漳州: 0.1 %潍坊: 0.1 %潍坊: 0.1 %澳门: 0.4 %澳门: 0.4 %珠海: 0.1 %珠海: 0.1 %石家庄: 0.6 %石家庄: 0.6 %福州: 0.1 %福州: 0.1 %红河: 0.1 %红河: 0.1 %约翰内斯堡: 0.1 %约翰内斯堡: 0.1 %纽约: 0.2 %纽约: 0.2 %绍兴: 0.1 %绍兴: 0.1 %自贡: 0.1 %自贡: 0.1 %艾因: 0.1 %艾因: 0.1 %芒廷维尤: 23.1 %芒廷维尤: 23.1 %芝加哥: 0.1 %芝加哥: 0.1 %苏州: 0.1 %苏州: 0.1 %莫斯科: 0.1 %莫斯科: 0.1 %葵涌: 0.9 %葵涌: 0.9 %衡水: 0.1 %衡水: 0.1 %西宁: 8.2 %西宁: 8.2 %西安: 0.5 %西安: 0.5 %诺沃克: 0.2 %诺沃克: 0.2 %贵阳: 0.2 %贵阳: 0.2 %赤峰: 0.1 %赤峰: 0.1 %达州: 0.1 %达州: 0.1 %连云港: 0.1 %连云港: 0.1 %遂宁: 0.1 %遂宁: 0.1 %邢台: 0.1 %邢台: 0.1 %邵阳: 0.1 %邵阳: 0.1 %郑州: 0.2 %郑州: 0.2 %都伯林: 0.1 %都伯林: 0.1 %酒泉: 0.1 %酒泉: 0.1 %重庆: 1.4 %重庆: 1.4 %金斯顿: 0.1 %金斯顿: 0.1 %银川: 0.1 %银川: 0.1 %锦州: 0.3 %锦州: 0.3 %长春: 0.4 %长春: 0.4 %长沙: 1.9 %长沙: 1.9 %雅安: 0.1 %雅安: 0.1 %青岛: 0.8 %青岛: 0.8 %香港: 0.7 %香港: 0.7 %马湾: 0.1 %马湾: 0.1 %鸡西: 0.1 %鸡西: 0.1 %鹰潭: 0.1 %鹰潭: 0.1 %麻坡: 0.1 %麻坡: 0.1 %黄山: 0.1 %黄山: 0.1 %龙岩: 0.1 %龙岩: 0.1 %其他其他AucklandBadenBass HillCantonCentral DistrictChinaDaculaHalfwegItalyJapanKao-sungKennedy TownMongoliaNorth PointSaitamaSingaporeTuen Mun San HuiUnited States[]上海上饶东京东莞东营中卫中山临沂云浮伦敦佛山佛罗里达州佳木斯保定元朗新墟凤凰城加利福尼亚州加州北京匹兹堡南京南宁南平南昌南通厦门台北台州合肥吉林呼和浩特哈尔滨唐山商丘喀拉拉嘉兴圣保罗埃德蒙顿墨尔本墨西哥城多伦多大庆大理大连天水围天津太原奥克兰安大略安庆安康官坑宜春宝鸡宿迁密蘇里城巴彦淖尔布里斯班常州广州廊坊延安张家口徐州怀化悉尼惠州意法半成都扬州承德抚顺拉斯维加斯揭阳新加坡无锡旧金山昆明晋城朝阳来宾杭州枣庄柳州栃木株洲森尼韦尔武汉氹仔沈阳沧州泉州泸州泽西洛杉矶洛阳济南济宁海口淄博深圳温哥华温州湛江滨州漳州潍坊澳门珠海石家庄福州红河约翰内斯堡纽约绍兴自贡艾因芒廷维尤芝加哥苏州莫斯科葵涌衡水西宁西安诺沃克贵阳赤峰达州连云港遂宁邢台邵阳郑州都伯林酒泉重庆金斯顿银川锦州长春长沙雅安青岛香港马湾鸡西鹰潭麻坡黄山龙岩

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1346) PDF downloads(305) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2695]YesterdayPV[4820]TodayIP[2404]TodayPV[4606]Online[74]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return